| Issue | Title | |
| Vol 2013, No 2 (2013) | Merck & Co. Changes Tack on Biosimilars with Samsung Bioepis Collaboration | Abstract |
| Heather Cartwright | ||
| Vol 2022, No 7 (2022) | Merck & Co. Collaborates with Orion to Develop and Commercialise ODM-208 for US$290 M | Abstract pdf html |
| Ashish Tripathi | ||
| Vol 2013, No 5 (2013) | Merck & Co. Collaborates with Pfizer and Abide Therapeutics with Aim of Bolstering Diabetes Portfolio | Abstract |
| Heather Cartwright | ||
| Vol 2020, No 11 (2020) | Merck & Co. Continues Oncology Expansion with US$2.75 B VelosBio Buy | Abstract pdf html |
| Michelle Liu | ||
| Vol 2018, No 11 (2018) | Merck & Co. Continues to Look at NK Cell Engager Therapies with Dragonfly Therapeutics Pact | Abstract pdf html |
| Michelle Liu | ||
| Vol 2014, No 6 (2014) | Merck & Co. Divests Nine Ophthalmology Brands to Japan’s Santen Pharmaceutical | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 4 (2011) | Merck & Co. Enhances its Emerging Markets Presence with Joint Venture with Sun Pharma | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 6 (2012) | Merck & Co. Forays into Biologic-Drug Conjugates in Collaboration with Ambrx | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 9 (2011) | Merck & Co. Forms Bispecific Antibody Collaboration with Zymeworks | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 2 (2012) | Merck & Co. Forms Joint Venture with Supera Farma Laboratorios to Increase its Presence in Brazil | Abstract |
| Heather Cartwright | ||
| Vol 2021, No 10 (2021) | Merck & Co. Gets Sotatercept with US$11.5 B Acceleron Buyout | Abstract pdf html |
| Sasha Yachu | ||
| Vol 2021, No 3 (2021) | Merck & Co. Hands Over US$1.85 B to Acquire Pandion Therapeutics | Abstract pdf html |
| Michelle Liu | ||
| Vol 2011, No 6 (2011) | Merck & Co. Joins Forces with Roche for Promotion of Victrelis™ | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 4 (2012) | Merck & Co. Licenses Endocyte’s Phase III Cancer Drug for a Potential US$1 B | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 1 (2012) | Merck & Co. Licenses Exelixis’ PI3K-Delta R&D Programme | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 10 (2011) | Merck & Co. Out-Licenses Gene Therapy Portfolio to Finnish Start-Up FKD Therapies | Abstract |
| Heather Cartwright | ||
| Vol 2013, No 5 (2013) | Merck & Co. Out-Licenses Second CNS Programme to Cerecor | Abstract |
| Heather Cartwright | ||
| Vol 2023, No 11 (2023) | Merck & Co. Pays Daiichi Sankyo US$4 B Upfront for Cancer ADCs | Abstract pdf HTML |
| Ayush Saxena | ||
| Vol 2022, No 7 (2022) | Merck & Co. Pays US$35 M Upfront for Kelun-Biotech’s ADC Oncology Drug | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2007, No 86 (2007) | Merck & Co. Signs Major Drug Delivery Deal with SurModics | Abstract pdf |
| Business Review Editor | ||
| Vol 2018, No 3 (2018) | Merck & Co. Signs Multibillion-Dollar Deal with Eisai for Lenvima® | Abstract pdf html |
| Heather Cartwright | ||
| Vol 2024, No 10 (2024) | Merck & Co. Signs US$1.9 B Pact with Mestag Therapeutics for Fibroblast Therapies | Abstract html pdf |
| Shweta Gupta | ||
| Vol 2007, No 87 (2007) | Merck & Co. Strengthens CV Pipeline with Selective Acquisition | Abstract pdf |
| Business Review Editor | ||
| Vol 2012, No 7 (2012) | Merck & Co. Strengthens its HIV Pipeline with Two Licensing Deals | Abstract |
| Heather Cartwright | ||
| Vol 2023, No 11 (2023) | Merck & Co. to Acquire Caraway Therapeutics for Up to US$610 M | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2024, No 6 (2024) | Merck & Co. to Acquire EyeBio for US$3 B to Expand Ophthalmology Pipeline | Abstract pdf html |
| Lalit Mishra | ||
| Vol 2024, No 2 (2024) | Merck & Co. to Acquire Harpoon Therapeutics for US$680 M | Abstract pdf html |
| Ayush Saxena | ||
| Vol 2010, No 10 (2010) | Merck & Co. to Acquire SmartCells and its Glucose-Responsive Insulin Technology | Abstract |
| Heather Cartwright | ||
| Vol 2016, No 6 (2016) | Merck & Co’s Neurology Boost with Afferent Acquisition | Abstract html pdf |
| Keshav Mahawar | ||
| Vol 2010, No 3 (2010) | Merck Acquires Millipore to Advance its Life Sciences Business | Abstract |
| PharmaDeals Analyst | ||
| Vol 2010, No 7 (2010) | Merck and Alectos Therapeutics to Identify and Develop Novel Drugs for Alzheimer’s Disease | Abstract |
| Heather Cartwright | ||
| Vol 2004, No 48 (2004) | Merck and BMS to Co-Promote Diabetes Drug | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 62 (2005) | Merck and Metabasis Target Metabolic Diseases | Abstract |
| Business Review Editor | ||
| Vol 2009, No 7 (2009) | Merck and Portola’s Agreement on Anticoagulant Drug | Abstract |
| Taskin Ahmed | ||
| Vol 2003, No 40 (2003) | Merck Backs Alnylam’s RNAi Technology | Abstract pdf |
| Business Review Editor | ||
| Vol 2019, No 5 (2019) | Merck Bets on HIF-2α Inhibitors with Peloton Purchase | Abstract pdf html |
| Michelle Liu | ||
| Vol 2008, No 92 (2008) | Merck Chooses Addex a Second Time | Abstract pdf |
| Business Review Editor | ||
| Vol 2025, No 7 (2025) | Merck Expands Respiratory Portfolio with US$10 B Acquisition of Verona Pharma | Abstract html pdf |
| Hitesh Udar | ||
| Vol 2020, No 1 (2020) | Merck Explores KRAS Inhibitors with US$2.55 B Taisho/Astex Deal | Abstract html pdf |
| Michelle Liu | ||
| Vol 2021, No 1 (2021) | Merck Forms NASH Therapy Alliance with Aligos to Bolster Liver Disease Pipeline | Abstract pdf html |
| Pratika Pahwa & Michelle Liu | ||
| Vol 2008, No 100 (2008) | Merck Heads Back to India for More Anti-Infective Programmes | Abstract pdf html |
| Sally Mardikian PhD | ||
| Vol 2012, No 2 (2012) | Merck KGaA Boosts its Late-Stage Pipeline by Licensing Threshold’s Hypoxia-Targeted Cancer Drug | Abstract |
| Heather Cartwright | ||
| Vol 2021, No 4 (2021) | Merck KGaA Expands Head and Neck Cancer Therapy Portfolio with Debiopharm’s Xevinapant | Abstract pdf html |
| Debadrita Paul & Michelle Liu | ||
| Vol 2002, No 30 (2002) | Merck KGaA Licenses Niaspan and Advicor from Kos | Abstract pdf |
| Business Review Editor | ||
| Vol 2023, No 11 (2023) | Merck KGaA Partners with Hengrui Pharma for Selective PARP1 Inhibitor and Antibody-Drug | Abstract html pdf |
| Ashish Tripathi | ||
| Vol 2024, No 3 (2024) | Merck KGaA Pays C4 Therapeutics US$16 M Upfront for Protein Degraders | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2023, No 12 (2023) | Merck KGaA Signs Licensing Agreement with Abbisko for Pimicotinib | Abstract pdf html |
| Lalit Mishra | ||
| Vol 2020, No 12 (2020) | Merck KGaA Strengthens Synthetic Lethality Pipeline with US$6.9 B Artios Alliance | Abstract pdf html |
| Michelle Liu | ||
| Vol 2025, No 5 (2025) | Merck KGaA to Acquire Rare Tumour Specialist SpringWorks Therapeutics for US$3.9 B | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2012, No 6 (2012) | Merck KGaA Ventures into Biosimilars in Collaboration with Dr. Reddy’s | Abstract |
| Heather Cartwright | ||
| Vol 2009, No 2 (2009) | Merck Makes Further Inroads into Biologicals | Abstract html |
| Taskin Ahmed | ||
| Vol 2005, No 61 (2005) | Merck Obtains License from BioXell to Develop TREM-1 Products | Abstract pdf |
| Business Review Editor | ||
| Vol 2011, No 1 (2011) | Merck Serono and Domain Therapeutics Partner to Develop Positive Allosteric Modulators for Parkinson’s Disease | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 9 (2011) | Merck Serono and F-star Form Next-Generation Antibody Development Pact | Abstract |
| Heather Cartwright | ||
| Vol 2009, No 3 (2009) | Merck Serono and Fast Forward to Speed Multiple Sclerosis Developments | Abstract |
| Taskin Ahmed | ||
| Vol 2012, No 9 (2012) | Merck Serono Licenses Global Rights to Symphogen’s Sym004 Cancer Antibody Mixture | Abstract |
| Heather Cartwright | ||
| Vol 2009, No 2 (2009) | Merck Serono Signs Multiple Sclerosis Deal with Ambrx | Abstract html |
| Taskin Ahmed | ||
| Vol 2008, No 101 (2008) | Merck Serono Signs North American Deals | Abstract pdf html |
| Taskin Ahmed | ||
| Vol 2019, No 10 (2019) | Merck Signs Another Deal with 4D Pharma to Strengthen its Vaccine Portfolio | Abstract pdf html |
| Sharath Chandra Nakka | ||
| Vol 2008, No 100 (2008) | Merck Signs Osteoporosis Deal with Japan Tobacco | Abstract pdf html |
| Taskin Ahmed | ||
| Vol 2020, No 9 (2020) | Merck Signs Two Oncology Collaborations with Seattle Genetics | Abstract pdf html |
| Michelle Liu | ||
| Vol 2023, No 3 (2023) | Merck Signs US$922.5 M Collaboration with OPKO Health for Epstein-Barr Virus Vaccine | Abstract pdf html |
| Lalit Mishra & Lucy Haggerty | ||
| Vol 2003, No 32 (2003) | Merck to Acquire Remaining 49% of Banyu for US$1.52 B | Abstract pdf |
| Business Review Editor | ||
| Vol 2009, No 3 (2009) | Merck to Merge with Schering-Plough in a US$41.1 B deal | Abstract |
| Taskin Ahmed | ||
| Vol 2019, No 12 (2019) | Merck Validates BTK Inhibitors with US$2.7 B ArQule Buy | Abstract pdf html |
| Michelle Liu | ||
| Vol 2021, No 2 (2021) | Merck Ventures Further into Natural Killer Therapies with US$1.9 B Artiva Alliance | Abstract pdf html |
| Michelle Liu | ||
| Vol 2004, No 50 (2004) | Merix and Kirin Collaborate on Dendritic Cell Vaccine Development | Abstract pdf |
| Business Review Editor | ||
| Vol 2009, No 12 (2009) | Merrimack and Cubist on a Biotech Acquisition Spree | Abstract |
| Taskin Ahmed | ||
| Vol 2008, No 102 (2008) | Merrion to Develop Insulin Drugs with Novo | Abstract pdf html |
| Taskin Ahmed | ||
| Vol 2010, No 4 (2010) | Mersana and Teva in USD 334 M deal for preclinical cancer drug | Abstract |
| Debbie Tranter | ||
| Vol 2012, No 3 (2012) | Mersana Therapeutics Raises Profile with Antibody-Drug Conjugate Collaboration with Endo | Abstract |
| Heather Cartwright | ||
| Vol 2008, No 94 (2008) | Merz Pharmaceutical GmbH | Abstract |
| Business Review Editor | ||
| Vol 2010, No 10 (2010) | Mesoblast and Cephalon in Largest Regenerative Medicine Deal to Date | Abstract |
| Heather Cartwright | ||
| Vol 2008, No 92 (2008) | Methylnaltrexone | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 52 (2004) | MGI Pharma’s US$122 M Oncology Spree | Abstract |
| Business Review Editor | ||
| Vol 2002, No 26 (2002) | Micrologix Licenses Anti-Infective to Fujisawa | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 56 (2005) | Micromet AG | Abstract pdf |
| Business Review Editor | ||
| Vol 2011, No 7 (2011) | Micromet Signs US$1 B BiTE® Antibody Collaboration with Amgen | Abstract |
| Heather Cartwright | ||
| Vol 2005, No 57 (2005) | Millennium and UCB Collaborate on Inflammation | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 50 (2004) | Millennium Grants GSK European Marking Rights to Integrilin® | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 31 (2002) | Millennium Initiates Cardiovascular Collaboration with The Cleveland Clinic | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 39 (2003) | Millennium, J&J and Velcade | Abstract |
| Business Review Editor | ||
| Vol 2021, No 6 (2021) | MiNA Therapeutics Gains Another Partner in Lilly for its saRNA Technology | Abstract pdf html |
| Michelle Liu | ||
| Vol 2011, No 11 (2011) | miRagen Receives Validation of its miRNA Platform with Servier Collaboration | Abstract |
| Heather Cartwright | ||
| Vol 2017, No 8 (2017) | Mitsubishi Pharma Acquires NeuroDerm for Parkinson’s Drug | Abstract pdf html |
| Jawala Prasad | ||
| Vol 2008, No 98 (2008) | Mitsubishi Tanabe Builds its Presence in North America | Abstract pdf html |
| Taskin Ahmed | ||
| Vol 2006, No 73 (2006) | MNLpharma Ltd | Abstract |
| Business Review Editor | ||
| Vol 2023, No 1 (2023) | Moderna Signs US$1.2 B Collaboration with Oncology Specialist CytomX | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2023, No 9 (2023) | Moderna Signs US$1.8 B Oncology Collaboration with Immatics | Abstract html pdf |
| Lucy Haggerty | ||
| Vol 2013, No 12 (2013) | Molecular Partners and Roche Collaborate to Develop Protein-Drug Conjugates in Oncology | Abstract |
| Heather Cartwright | ||
| Vol 2006, No 78 (2006) | MolMed SpA | Abstract |
| Business Review Editor | ||
| Vol 2006, No 75 (2006) | Momenta and Sandoz on a Roll | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 86 (2007) | Monte Carlo | Details jpg |
| Business Review Editor | ||
| Vol 2008, No 91 (2008) | MorphoSys AG | Abstract |
| Business Review Editor | ||
| Vol 2004, No 49 (2004) | MorphoSys and Novartis Sign Antibody Agreement | Abstract pdf |
| Business Review Editor | ||
| Vol 2021, No 6 (2021) | MorphoSys Expands Oncology Footprint with Constellation and Royalty Pharma | Abstract pdf html |
| Neha Madhwani & Michelle Liu | ||
| Vol 2022, No 6 (2022) | MorphoSys Out-licenses Two Oncology Antibodies to HIBio | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2011, No 5 (2011) | Mundipharma Gains Commercialisation Rights to Allos Therapeutics’ Folotyn® Outside of North America | Abstract |
| Heather Cartwright | ||
| Vol 2006, No 74 (2006) | Mundipharma to Develop Sosei’s Fentanyl Pain Spray | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 58 (2005) | Mylan and King Terminate Merger | Abstract pdf |
| Business Review Editor | ||
| 1601 - 1700 of 2613 Items | << < 12 13 14 15 16 17 18 19 20 21 > >> | |